trial

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

NCTId NCT02597439
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 145 (actual)
Sponsored by Rene Kahn
Primary completion 2023-02-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
145 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-09-30
Primary completion
2023-02-01
Eligibility
ALL · 13 Years · 20 Years

Interventions & indications

Drugs
Omega-3 fatty acids

Sponsors

Rene KahnLead Sponsor

Investigators

1
René Kahn, Prof. Dr.Study Chair

Sites

14 total
Vienna, AustriaTübingen, GermanyPetah Tikva, IsraelRamat Gan, IsraelRome, ItalyRome, ItalyUtrecht, NetherlandsBergen, NorwayBarcelona, SpainBarcelona, SpainMadrid, SpainSantander, Spain

Facts & assertions

4 sourced
Enrollment
145
Phase
PHASE4
Primary Completion Date
2023-02-01
Status
COMPLETED
relationships
The graph out of here
drug
Omega-3 fatty acids
drug
lead_sponsor
Rene Kahn
company
indication
Ultra High Risk for Psychosis
indication
Psychotic Disorders
indication
investigator
René Kahn, Prof. Dr.
person